Multiple immunofluorescence assay identifies upregulation of Active β-catenin in prostate cancer
Puig Rosell, Pere (R&D Department, Atrys Health)
Erill, Nadina (R&D Department, Atrys Health)
Terricabras, Marta (R&D Department, Atrys Health)
Subirana, Isaac (R&D Department, Atrys Health)
González-García, Judit (R&D Department, Atrys Health)
Asensi-Puig, Adrià (R&D Department, Atrys Health)
Donovan, Michael J. (Icahn School of Medicine at Mount Sinai, MSSM)
Mengual, Lourdes (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Agulló-Ortuño, M. Teresa (Instituto de Investigación Hospital. Pathology Department, Urology Department and Laboratory of Translational Oncology)
Olivan, M. (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Alcaraz Asensio, Antonio (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Lopez-Martin, Jose A (Instituto de Investigación Hospital. Pathology Department, Urology Department and Laboratory of Translational Oncology)
de Torres, Inés (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Rodríguez-Peralto, José Luis (Instituto de Investigación Hospital. Pathology Department, Urology Department and Laboratory of Translational Oncology)
Rodríguez-Antolín, Alfredo (Instituto de Investigación Hospital. Pathology Department, Urology Department and Laboratory of Translational Oncology)
Morote Robles, Juan (Hospital Universitari Vall d'Hebron. Institut de Recerca)
González-Rumayor, Víctor (R&D Department, Atrys Health)
Universitat Autònoma de Barcelona

Date:	2019
Abstract:	To apply a systems pathology-based approach to the quantification of nuclear Active β-catenin and human leukocyte antigen class I, and assess the biomarker involvement in a cohort of prostate tumor patients. The systems pathology approach applied allows a precise quantification of the marker expression in the different cell compartments as well as the determination of the areas that coexpress two markers. Our data shows that the accumulation of β-catenin in the nuclear compartment is significantly decreased in the adjacent normal areas when compared to tumor of the same patients (p < 0. 001). In conclusion, the application of this novel multiple immunofluorescence assay demonstrates that the upregulation of Active β-catenin is a relatively common feature of prostate tumor development, and further supports the activation of the Wnt/β-catenin pathway in prostate cancer progression. The online version of this article (10. 1186/s13104-019-4100-z) contains supplementary material, which is available to authorized users.
Grants:	Ministerio de Economía y Competitividad IPT‑2012‑1311‑300000
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Active β-catenin ; HLA class1 ; Wnt/β-catenin pathway ; Prostate cancer ; Systems pathology
Published in:	BMC research notes, Vol. 12 (january 2019) , ISSN 1756-0500

DOI: 10.1186/s13104-019-4100-z
PMID: 30700322

5 p, 753.9 KB

The record appears in these collections:
Articles > Research articles
Articles > Published articles